Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026-Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage ...
Addex spin-out Neurosterix begins phase 1 study with M4 PAM - NTX-253 for schizophrenia: Geneva, Switzerland Thursday, January 8, 2026, 12:00 Hrs [IST] Addex Therapeutics, a clini ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback